-
A Breakthrough in Pediatric Protection: Pfizer’s New Pneumococcal Vaccine Candidate
NYSE: $PFE Positive Momentum in Vaccine Development Pfizer has officially announced encouraging results from a Phase 2 clinical trial for its latest investigational vaccine candidate: a 25-valent pneumococcal conjugate vaccine (PCV). This development marks a significant potential step forward in protecting infants and children from invasive pneumococcal disease, a condition that remains a global health…
-
New Hope: FDA Approves Pfizer’s Tukysa Regimen for Metastatic Breast Cancer
NYSE: $PFE A Significant Milestone in Oncology The landscape of breast cancer treatment has shifted once again as the FDA has officially granted approval for a new regimen involving Pfizer’s Tukysa (tucatinib). This approval marks a critical step forward for patients battling HER2-positive metastatic breast cancer, particularly in the front-line maintenance setting. Understanding the New…
-
Pfizer’s Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study
NYSE: $PFE NEW YORK–(BUSINESS WIRE) October 01, 2026 — Pfizer Inc. (NYSE: PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its… Source: Read More
-
Updated COVID-19 Protection: FDA Approves New Pfizer-BioNTech Comirnaty Vaccine
NYSE: $PFE A New Development in COVID-19 Prevention As we continue to navigate the evolving landscape of respiratory health, the U.S. Food and Drug Administration (FDA) has taken a significant step forward. Pfizer and BioNTech have officially received FDA approval for their updated Comirnaty COVID-19 vaccine, specifically adapted to target more recent circulating variants. What…
-
FREE BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 02-08-2026 TO 02-14-2026
Well well, The Seattle Seahawks take the Win in Super Bowl LX. This is what Google’s Gemini summarized regarding stock market prediction after the Win. And now, back to the BIO-TECH STOCK CATALYST REPORT. We’re excited to announce the release of our latest free bio tech stock catalyst report for the upcoming week. This new…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF 01-18-2026 TO 01-24-2026
We’re excited to announce the release of our latest bio tech stock catalyst report for the upcoming week. This new stock report highlights bio tech companies that have an upcoming important event to help traders and investors make informed decisions in today’s dynamic environment. Each stock symbol is a link to a stock quote page…
$ABBV, $AZN, $ELDN, $GMAB, $GNLX, $LLY, $LTRN, $MNKD, $NOV, $NVO, $NVS, $PFE, $SNY, biopharmaceutical, clinical-research, fda, new drug application, pr-newswire, press-releases